著者
立花 哲也 鈴木 愛 高森 基史 伊能 智明 青木 美穂子 千葉 博茂
出版者
Japanese Society of Psychosomatic Dentistry
雑誌
日本歯科心身医学会雑誌 (ISSN:09136681)
巻号頁・発行日
vol.17, no.1, pp.21-25, 2002-06-25 (Released:2011-09-20)
参考文献数
17

Lafutidine (FRG-8813) is a new H2-receptorantagonist that not only has a strong inhibitory effect on gastric secretion but also augments the gastric mucosa protection factor and dilate arterious in the gastric submucosa and enhances gastric mucosal blood flow via capusaicinsensitive afferent neurons.Its presence in the tongue too, suggests that lafutidine may be effective for patients diagnosed with glossodynia. This treatment was attempted with 50 glossodynia patients, who received lafutidine in doses of 10mg twice daily for 8 weeks.The pain amelioration rates (reduced and better) were 54.0%(27/50 cases) after 2 weeks, 60.0%(30/50 cases) after 4 weeks, 80.0%(40/50 cases) after 6 weeks, and 84.0%(42/50 cases) after 8 weeks. The pain level on VAS was 46.8mm on average before administration, and 12.1mm on average after 8 weeks.The administration of lafutidine exhibited good clinical efficacy, safety and utility in the treatment of glossodynia.